World’s First Ever Successful Heart Xenotransplantation Happens By Innovative Preservation Technology of XVIVO

The world’s first successful pig is a human heart transplant, a breakthrough in the field of transplantation. A team from the University of Maryland School of Medicine performed the procedure. The recipient was a 57-year-old terminal patient who received a heart transplant from a genetically modified pig. After harvest, the pig’s heart was stored with a XVIVO cardiac enhancer and proprietary solution until the heart was transplanted.

Lack of agency is the biggest challenge facing resettlement. As a result, fewer patients with end-stage heart disease have the opportunity to be transplanted, and many more die while waiting for a new organ. The potential solution to this critical defect is xenotransplantation, which refers to transplantation between species.

Earthquake research has shown that XVIVOs have long-term survival after transplanting the heart from genetically modified pigs to primitives using heart protection technology. Based on this large-scale study, the first human heart transplant from a genetically modified pig to a human was performed.

The patient did not qualify for a normal human body transplant, and because of his last heart attack, xenotransplant was his only option for survival. He is still doing well three days after the historic surgery.

XVIVO in Lund, Sweden, in collaboration with Professor Stig Stein and Igelösa Life Sciences, has developed a new way to optimize the storage and transportation of donated hearts through the NIHP. The XVIVO heart spray device keeps the donor’s heart at 8 degrees Celsius, while also being able to absorb oxygenated, appropriate solution through the organ. For the first time, human transplants have been successfully transplanted, and several clinical trials are being carried out at leading transplant centers in Europe and Australia. In 2019, XVIVO’s new heart technology was awarded a “breakthrough device designation” by the U.S. Food and Drug Administration (FDA) and is scheduled for a multi-center clinical trial in the United States in 2022.

The new cardiac care technique aims to transplant clinical human beings into humans, but it has also been shown to play an important role in long-term survival in pre-clinical research by using pig heart transplants as cannabis transplants by reducing the risk of early organ dysfunction.

Mohammed M. Mohiuddin, a professor of surgery at the University of Maryland School of Medicine and a doctorate in medicine, has been involved in the field of canopy transplantation since 1992. We did that. Many years of research and initial efforts by us and others have led us to this point. There is no other treatment that could be life-threatening for a transplanted patient. I’m glad he’s on his way forward, and he’s in a very good mood. Without XVIVO’s new heart technology, this transplant would never have happened, and I am grateful for all the support we have received, “said Professor Mohiddin.

“In the future, where xenotransplants can help to address organ donation shortcomings, we are truly living our dream of having no new members waiting for new members. We have always been at the forefront of institutional technology and innovation. Therefore, being a part of this heart-transplanted pig for the first time, which can bring additional hope to patients on the waiting list, is nothing but a real honor. For me, this is the final proof that the collaboration between scientists, clinicians and the industry will make the world better, “said Doug Anderson, CEO of XVIVO.

Leave a Comment